hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1

Xin He1, Saijun Fan1

  • 1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin 300192, P.R. China.

Oncology Reports
|December 30, 2017
PubMed

Insights

MicroRNA-212 (miR-212) contributes to glioma radioresistance by inhibiting radiation-induced apoptosis. This microRNA (miRNA) targets BRCA1, suggesting the miR-212/BRCA1 axis is a potential target for improving glioma radiotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma (GBM) radioresistance is a significant clinical challenge.
  • Patient response to radiotherapy for glioma is highly variable.
  • MicroRNAs (miRNAs) regulate diverse biological processes, including cellular response to radiation.

Purpose of the Study:

  • To identify specific miRNAs involved in the radioresistance of glioma cells.
  • To elucidate the molecular mechanisms underlying miRNA-mediated radioresistance in glioma.
  • To investigate the potential of targeting miRNAs for enhancing glioma radiotherapy.

Main Methods:

  • Human glioma cell lines (U251, U-118MG, SHG-44) were exposed to gamma-ray radiation.
  • miRNA expression profiling was performed using miRNA chip arrays and quantitative real-time PCR.
  • Functional studies involved miRNA mimic transfection, colony formation assays, and Western blot analysis of apoptosis-related proteins.
  • Bioinformatic tools and luciferase reporter assays were used to identify and validate miRNA targets, specifically focusing on BRCA1.

Main Results:

  • miR-212 expression was significantly altered in glioma cells post-irradiation.
  • Overexpression of miR-212 attenuated radiation-induced apoptosis in glioma cells, contributing to radioresistance.
  • miR-212 directly targets the 3'-untranslated region of BRCA1, negatively regulating its expression.
  • BRCA1 expression levels correlated with radiosensitivity in glioma cells.

Conclusions:

  • The miR-212/BRCA1 axis plays a critical role in modulating glioma cell response to radiation.
  • miR-212 promotes radioresistance by downregulating BRCA1 and inhibiting apoptosis.
  • Targeting the miR-212/BRCA1 pathway represents a potential therapeutic strategy to overcome radioresistance in glioma treatment.

Related Concept Videos

Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Cell Potential and Free Energy02:58

Cell Potential and Free Energy

Thermodynamics of a Redox Reaction
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
46.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
934